Notel Biotech announced that it has recently received the “Drug Registration Certificate” for atosiban acetate injection approved and issued by the State Drug Administration. The drug has two specifications: 0.9 ml: 6.75 mg and 5 ml: 37.5mg. The validity period is 18 months, and the approval number is valid until 2030. This injection is a selective oxytocin receptor antagonist and is suitable for pregnant women with signs of premature labor. Approval is the company's expansion in the field of assisted reproductive medicine, which is beneficial to improving competitiveness, but product sales are affected by many factors, and the short-term impact on performance is uncertain.

Notel Biotech announced that it has recently received the “Drug Registration Certificate” for atosiban acetate injection approved and issued by the State Drug Administration. The drug has two specifications: 0.9 ml: 6.75 mg and 5 ml: 37.5mg. The validity period is 18 months, and the approval number is valid until 2030. This injection is a selective oxytocin receptor antagonist and is suitable for pregnant women with signs of premature labor. Approval is the company's expansion in the field of assisted reproductive medicine, which is beneficial to improving competitiveness, but product sales are affected by many factors, and the short-term impact on performance is uncertain.